Stock Events

Stock Events

Stoke Therapeutics 

$26.29
34
-$0.06-0.23%Friday 20:00
+$0.71+2.7%Friday 23:30After hours

Statistics

Day High
26.33
Day Low
26.19
52W High
40.22
52W Low
20.32
Volume
94,620
Avg. Volume
-
Mkt Cap
1.7B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 29Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-1.08
-0.09
0.91
1.9
Expected EPS
-0.929138
Actual EPS
-1.08

Financials

-3.73%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
184.42MRevenue
-6.89MNet Income

Analyst Ratings

$45.14Average Price Target
The highest estimate is ⁦60.00⁩.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow STOK. It's not an investment recommendation.
NVIDIA
6
NVDA
Meta Platforms
6
META
PayPal
6
PYPL
Microsoft
5
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ionis Pharmaceuticals
IONS
Mkt Cap7.24B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, similar to Stoke's focus on treating genetic diseases by targeting RNA.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapies, competing in the same space as Stoke with a focus on genetic disorders.
Sarepta Therapeutics
SRPT
Mkt Cap1.85B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, directly competing with Stoke's approach to genetic conditions.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including genetic disorders, competing with Stoke.
PTC Therapeutics
PTCT
Mkt Cap5.3B
PTC Therapeutics operates in the field of genetic disorders by targeting post-transcriptional control mechanisms, which is a similar area of focus as Stoke.
Ultragenyx Pharmaceutical
RARE
Mkt Cap1.5B
Ultragenyx Pharmaceutical works on developing therapies for rare and ultra-rare genetic diseases, making it a competitor in the same niche as Stoke.
Editas Medicine
EDIT
Mkt Cap402.38M
Editas Medicine is involved in genome editing technology, a different but competing approach to treating genetic diseases compared to Stoke's RNA-focused strategies.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases, including genetic disorders, offering a competing technology to Stoke's RNA approach.
Intellia Therapeutics
NTLA
Mkt Cap1.72B
Intellia Therapeutics is a leading genome editing company that competes with Stoke by offering potential treatments for genetic diseases through a different mechanism.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics develops precision genetic medicines through base editing, a novel approach that competes with Stoke's RNA-targeted therapies for genetic diseases.

About

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Show More
CEO
Ian F. Smith
Employees
170
Country
United States
ISIN
US86150R1077
WKN
000A2PLTL

Listings

STU
DE
0GT.STU
MU
DE
0GT.MU
F
DE
0GT.F
XNAS
US
STOK

0 Comments

Share your thoughts

FAQs

What is Stoke Therapeutics stock price today?▼
The current price of STOK is $26.29 USD — it has decreased by -0.23% in the past 24 hours. Watch Stoke Therapeutics stock price performance more closely on the chart.
What is Stoke Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Stoke Therapeutics stocks are traded under the ticker STOK.
Is Stoke Therapeutics stock price growing?▼
STOK stock has risen by +3.26% compared to the previous week, the month change is a +2.62% rise, over the last year Stoke Therapeutics has showed a -12.48% decrease.
What is Stoke Therapeutics market cap?▼
Today Stoke Therapeutics has the market capitalization of 1.7B
When is the next Stoke Therapeutics earnings date?▼
Stoke Therapeutics is going to release the next earnings report on March 16, 2027.
What were Stoke Therapeutics earnings last quarter?▼
STOK earnings for the last quarter are -1.08 USD per share, whereas the estimation was -0.93 USD resulting in a -16.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Stoke Therapeutics revenue for the last year?▼
Stoke Therapeutics revenue for the last year amounts to 184.42M USD.
What is Stoke Therapeutics net income for the last year?▼
STOK net income for the last year is -6.89M USD.
How many employees does Stoke Therapeutics have?▼
As of November 2, 2026, the company has 170 employees.
In which sector is Stoke Therapeutics located?▼
Stoke Therapeutics operates in the Health & Wellness sector.
When did Stoke Therapeutics complete a stock split?▼
Stoke Therapeutics has not had any recent stock splits.
Where is Stoke Therapeutics headquartered?▼
Stoke Therapeutics is headquartered in BEDFORD, United States.